Stock Track | BAO PHARMA-B Soars 5.02% Intraday on Controlling Shareholder Confidence and New Product Approval

Stock Track05-13 10:07

BAO PHARMA-B's stock price surged 5.02% during intraday trading on Wednesday, driven by multiple positive developments that boosted investor confidence.

The company's controlling shareholder group, led by Chairman Dr. Liu Yanjun, announced plans to increase holdings of up to 38,893,900 H shares through open market transactions within three months, signaling strong internal confidence in the company's long-term value. Currently, the controlling shareholder group holds approximately 40.57% of the issued shares.

Additionally, the company received approval from China's National Medical Products Administration for the commercial launch of its injectable human hyaluronidase, adding a new commercialized product to its pipeline and strengthening future earnings expectations. The shareholders' general meeting also approved a share repurchase authorization, with the company confirming that repurchase funds are legally compliant and will not affect normal operations.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1177039394?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-13 10:07","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1177039394","market":"us","top_or_hot":-1,"title":"Stock Track | BAO PHARMA-B Soars 5.02% Intraday on Controlling Shareholder Confidence and New Product Approval","media":"Stock Track","content":"<p>BAO PHARMA-B's stock price surged 5.02% during intraday trading on Wednesday, driven by multiple positive developments that boosted investor confidence.</p><p>The company's controlling shareholder group, led by Chairman Dr. Liu Yanjun, announced plans to increase holdings of up to 38,893,900 H shares through open market transactions within three months, signaling strong internal confidence in the company's long-term value. Currently, the controlling shareholder group holds approximately 40.57% of the issued shares.</p><p>Additionally, the company received approval from China's National Medical Products Administration for the commercial launch of its injectable human hyaluronidase, adding a new commercialized product to its pipeline and strengthening future earnings expectations. The shareholders' general meeting also approved a share repurchase authorization, with the company confirming that repurchase funds are legally compliant and will not affect normal operations.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | BAO PHARMA-B Soars 5.02% Intraday on Controlling Shareholder Confidence and New Product Approval</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | BAO PHARMA-B Soars 5.02% Intraday on Controlling Shareholder Confidence and New Product Approval\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-05-13 10:07</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>BAO PHARMA-B's stock price surged 5.02% during intraday trading on Wednesday, driven by multiple positive developments that boosted investor confidence.</p><p>The company's controlling shareholder group, led by Chairman Dr. Liu Yanjun, announced plans to increase holdings of up to 38,893,900 H shares through open market transactions within three months, signaling strong internal confidence in the company's long-term value. Currently, the controlling shareholder group holds approximately 40.57% of the issued shares.</p><p>Additionally, the company received approval from China's National Medical Products Administration for the commercial launch of its injectable human hyaluronidase, adding a new commercialized product to its pipeline and strengthening future earnings expectations. The shareholders' general meeting also approved a share repurchase authorization, with the company confirming that repurchase funds are legally compliant and will not affect normal operations.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02659","symbol_name":"宝济药业-B","start_time":0,"source_url":"","article_id":"1177039394","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1177039394","pubTimestamp":1778638055,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"BAO PHARMA-B's stock price surged 5.02% during intraday trading on Wednesday, driven by multiple positive developments that boosted investor confidence.The company's controlling shareholder group,...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02659":"宝济药业-B"},"translate_title":"个股赛道|控股股东信心及新品获批宝药业-B盘中大涨5.02%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02659":1},"content_text":"BAO PHARMA-B's stock price surged 5.02% during intraday trading on Wednesday, driven by multiple positive developments that boosted investor confidence.The company's controlling shareholder group, led by Chairman Dr. Liu Yanjun, announced plans to increase holdings of up to 38,893,900 H shares through open market transactions within three months, signaling strong internal confidence in the company's long-term value. Currently, the controlling shareholder group holds approximately 40.57% of the issued shares.Additionally, the company received approval from China's National Medical Products Administration for the commercial launch of its injectable human hyaluronidase, adding a new commercialized product to its pipeline and strengthening future earnings expectations. The shareholders' general meeting also approved a share repurchase authorization, with the company confirming that repurchase funds are legally compliant and will not affect normal operations.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1177039394","isCrawlerRequest":true}